Читать книгу Anti-Aging Therapeutics Volume XV - A4M American Academy - Страница 26

1.Zs.-Nagy I. “Is consensus in anti-aging medical intervention an elusive expectation or a realistic goal?” Archives of Gerontology and Geriatrics, Volume 48 Issue 3; May-June 2009, 271-276.

2.Interview with Tanjung Subrata, MD, 16 September 2013.

3.Interview with Tim Bolen, 30 July 2013.

4.Perls TT, Reisman NR, Olshansky SJ. "Provision or Distribution of Growth Hormone for 'Anti-Aging': Clinical and Legal Issues." JAMA. 2005 Oct 26;294(16):2086-90.

5.Epstein D. “US sprinter Tyson Gay linked to anti-aging specialist,” SI.com; 16 July 2013.

6.Paragraph excerpted from White Paper “Guidance for Physicians on Hormone Replacement Therapy”; A4M, May 2007; available at: http://www.worldhealth.net/white-papers-official-statements/

7.Interview with Robert Goldman, M.D., Ph.D., D.O., FAASP, 27 July 2013.

8.Statement of Louis Underwood, M.D., "Abuse of Steroids in Amateur and Professional Athletics," Hearing Before the Subcommittee on Crime/ House Committee on the Judiciary, March 22, 1990).

9.Interview with Rick Collins, JD, CSCS, www.steroidlaw.com, September 2013.

10.Mitchell, S.; HGH illegal as anti-aging treatment: United Press International (UPI), Oct. 25, 2005.

11.Mollica M. “Testosterone Replacement Therapy – Why Is It So Controversial?”; http://www.brinkzone.com/bodybuilding/testosterone-replacement-therapy-why-is-it-so-controversial/; July 20, 2012.

12.Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323:1-6.

13.Gotherstrom G., et.al. "A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices" Journal of Clinical Endocrinology and Metabolism, 86 (10): 4657-65, Oct. 2001.

14.Gibney J, et. al., "The Effects of 10 Years of Recombinant Human Growth Hormone, (GH) in Adult GH-Deficient Patients", The Journal of Clinical Endocrinology and Metabolism, Volume 84, Number 8, August 1999.

15.Cappola AR et al. Association of IGF-I levels with muscle strength and mobility in older women. J Clin Endocrinol Metab 2001 Sep;86(9):4139-46.

16.Aleman A. et al. Insulin-Like Growth Factor-I and Cognitive Function in Healthy Older Men J Clin Endocrinol Metab 84:471475, 1999.

17.Sugimoto T et al. Effect of recombinant human growth hormone in elderly osteoporotic women. Clin Endocrinol (Oxf) 1999 Dec;51(6):715-724.

18.Napoli R et al. J Am Coll Cardiol 2002 Jan 2;39(1):90-5.

19.Johannsson G et al. GH treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism and reduces diastolic BP. J Clin Endocinol Metab 1997;82:727-734.

20.Albert SG et al. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. Clin Endocrinol Metab. 2004 Feb;89(2):695-701.

21.Nam SY et al. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.

22.Paragraph excerpted from Rothenberg R, et al. “Hormone Optimization: Evidence Based Practical Management.” In Encyclopedia of Clinical Anti-Aging Medicine & Regenerative Biomedical Technologies, A4M, 2012, pp. 281-342.

23.Besson A et al. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab. 2003 Aug; 88(8):3664-7.

24.Ruiz-Torres A. and Soares de Melo Kirzner M. “Ageing and Longevity Are Related to Growth Hormone/Insulun-Like Growth Factor-1 Secretion.” Gerontology 2002; 48:401-407.

25.Stochholm, K et al. Mortality and GH Deficiency a Nationwide Study. European Journal of Endocrinology. (2007)157 9-18

26.The Journals of Gerontology:Series A, Vol. 67A, Issue 6; June 2012; http://biomedgerontology.oxfordjournals.org/content/67A/6.toc

27.Yusuke Higashi, Sergiy Sukhanov, Asif Anwar, Shaw-Yung Shai, Patrice Delafontaine. “Aging, Atherosclerosis, and IGF-1.” J Gerontol A Biol Sci Med Sci (2012) 67A (6): 626-639.

28.Zoltan Ungvari and Anna Csiszar. “The Emerging Role of IGF-1 Deficiency in Cardiovascular Aging: Recent Advances.” J Gerontol A Biol Sci Med Sci (2012) 67A (6): 599-610.

29.Yancy CW, Jessup M, Bozkurt B, Masoudi FA, et al; ACCF/AHA Task Force Members. “2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.” J Am Coll Cardiol. 2013 Jun 5.

30.Savine R. et al. Growth hormone replacement for the somatopause. Horm Res 2000;53 Suppl 3:37-4

31.Wuster C, Melchinger U, Eversmann T, Hensen J, Kann P, von zur Muhlen A, Ranke MB, Schmeil H, Steinkamp H, Tuschy U. Reduced incidence of side-effects of growth hormone substitution in 404 patients with hypophyseal insufficiency. Results of a multicenter indications Study. Med Klin 1998 Oct 15;93(10):585-91.

32.Ingermann AR, Yang YF, Han J, Mikami A, Garza AE, Mohanraj L, Fan L, Idowu M, Ware JL, Kim HS, Lee DY, Oh Y. Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem. 2010 Sep 24;285(39):30233-46.

33.Scirè G, Del Bianco C, Spadoni GL, Cianfarani S. Growth hormone therapy does not alter the insulin-like growth factor-I/insulin-like growth factor binding protein-3 molar ratio in growth hormone-deficient children. J Endocrinol Invest. 2008 Feb;31(2):153-8.

34.Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol (Oxf). 2006 Feb;64(2):115-21.

35.Molitch ME. Diagnosis of GH deficiency in adults--how good do the criteria need to be? J Clin Endocrinol Metab. 2002 Feb;87(2):473-6.

36.Svensson J, et al. J Clin Endocrinol Metab. 2004;89(7):3306-12.

37.Eiser C, et al. Growth Hormone Treatment and Quality of Life among Survivors of Childhood Cancer. Horm Res. 2005; 633(6):300-4.

38.Zumkeller W, et al. _Expression and synthesis of insulin-like growth factor-binding proteins in human glioma cell lines. Int J Oncol. 1998 Jan;12(1)129-35.

39.Gielen SC, et al. Steroid-modulated proliferation of human endometrial carcinoma cell lines: any role for insulin-like growth factor signaling? J Soc Gynecol Investig. 2005 Jan;12(1):58-64.

40.Bach LA, Headey SJ, Norton RS. IGF-binding proteins the pieces are falling into place. Trends Endocrinol Metab. 2005 July;16(5):228-34.

41.Swerdlow AJ, et al. J Clin Endocrinol Metab 2000;85(12):4444-9.

42.Tacke J, et al. JPEN J Parenter Enteral Nutr 2000;24(3):140-4.

43.Critical Evaluation of the Safety of Recombinant GH Administration: Statement from the Growth Hormone Research Society, J Clin Endo Metab, May 2001.

44.Gardner et al. "Effects of dietary carbohydrate on fasting levels of human growth hormone and cortisol," Proceedings of the Soc for Exper Biol and Med, 1982, 36-40.

45.US District Court, District of Nevada Case #3:06-CR-147-BES-VPC, USA vs. James W. Forsythe.

46.Interview with James Forsythe, M.D., HMD, 18 September 2013.

47.Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994;78:1360-1367. Erratum in: J Clin Endocrinol Metab 1995;80:2799.

48.Rabijewski M, Zgliczyński W. Positive effects of DHEA therapy on insulin resistance and lipids in men with angiographically verified coronary heart disease--preliminary study]. Endokrynol Pol. 2005 Nov-Dec;56(6):904-10.

49.Baulieu E.E., Thomas G., Legrain S., Lahlou N., Roger M., Debuire B., Faucounau V., Girard L., Hervy M.P., Latour F., Leaud M.C., Mokrane A., Pitti-Ferrandi H., Trivalle C., de Lacharriere O., Nouveau S., Rakoto-Arison B., Souberbielle J.C., Raison J., Le Bouc Y., Raynaud A., Girerd X., Forette F. (2000). Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA, 97(8):4279–4284.

50.Baulieu E.E. (1996). Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metabo, 81:3147–3151.

51.Stuckelberger A. (2008). Anti-Ageing Medicine : Myths and Chances. ETH Verlag, Zurich, Switzerland. e-book in open access: http://www.vdf.ethz.ch/service/3225/9783728132253_anti-ageing-medicine_oa.pdf

52.Daniel M Kelly and T Hugh Jones. “Testosterone: a vascular hormone in health and disease,” J Endocrology 217:3 R47–R71.

53.Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart. 2004 Apr;90(4):446-7.

54.Malkin CJ et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men J Clin Endocrinol Metab. 2004 Jul; 89(7):3313-8.

55.Turhan S et al. The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis. 2007 May; 18(3):159-62.

56.Rosano GM et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999 Apr 6; 99(13):1666-70

57.Hak, Elisabeth et al. Low Levels of Endogenous Androgens Increase the Risk of Atherosclerosis in Elderly Men: The Rotterdam Study. The Journal of Clinical Endocrinology & Metabolism Vol. 87, 2002, No. 8 3632-3639

58.Boyanov MA et al. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003 Mar;6(1):1-7.

59.Vakkat Muraleedharan and T. Hugh Jones. “Review: Testosterone and the metabolic syndrome,” Therapeutic Advances in Endocrinology and Metabolism 2010 Oct;1(5):207-23.

60.Bhasin S. et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997 Feb; 82(2):407-13.

61.Mudali S, Dobs AS. Effects of testosterone on body composition of the aging male. Mech Ageing Dev. 2004 Apr; 125(4):297-304

62.LeBlanc ES, Wang PY, Janowsky JS, Neiss MB, Fink HA, Yaffe K, Marshall LM, Lapidus JA, Stefanick ML, Orwoll ES; Osteoporotic Fractures in Men (MrOS) Research Group. Association between sex steroids and cognition in elderly men. Clin Endocrinol (Oxf). 2010 Mar;72(3):393-403.

63.Ekaterina L. Kovacheva, Amiya P. Sinha Hikim, Ruoqing Shen, Indranil Sinha, Indrani Sinha-Hikim. “ Testosterone Supplementation Reverses Sarcopenia in Aging through Regulation of Myostatin, c-Jun NH2-Terminal Kinase, Notch, and Akt Signaling Pathways.” Endocrinology, Feb. 2010; 151(2):628–638.

64.Moffat SD, Resnick SM. Long-term measures of free testosterone predict regional cerebral blood flow patterns in elderly men.Neurobiol Aging. 2006 May 11

65.Gouras GK et al. Proc Natl Acad Sci U S A 2000 Feb 1; 97(3):1202-5

66.Tan RS. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male. 2003 Mar; 6(1):13-7.

67.Janowsky JS. Thinking with your gonads: testosterone and cognition. Trends Cogn Sci. 2006 Feb;10(2):77-82.

68.Holland J, Bandelow S, Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas. 2011;69:322-337.

69.O'Connor DB, Archer J, Hair WM, Wu FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol Behav. 2002;75:557-566.

70.Aydogan U, Aydogdu A, Akbulut H, Sonmez A, Yuksel S, Basaran Y, Uzun O, Bolu E, Saglam K. Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions. Endocr J. 2012 Aug 31.

71.Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011;8:3204-3213.

72.Somboonporn W., Davis S., Seif M.W. and Bell R. (2005). Testosterone for peri- and postmenopausal women. Cochrane Database of Systematic Reviews, Issue 4.

73.Rhoden EL, Averbeck MA. [Prostate carcinoma and testosterone: risks and controversies]. Arq Bras Endocrinol Metabol. 2009 Nov;53(8):956-62.

74.Cooper CS et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men J Urol 1998 Feb; 159(2):441-3

75.Morales A. Monitoring androgen replacement therapy: testosterone and prostate safety.J Endocrinol Invest. 2005; 28(3 Suppl):122-7

76.Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999 Sep 1; 59(17):4161-4

77.Morley JE. Testosterone replacement and the physiologic aspects of aging in men.Mayo Clin Proc. 2000 Jan; 75 Suppl: S83-7

78.Gould DC, Kirby RS Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?Prostate Cancer Prostatic Dis. 2006;9(1):14-8

79.Agarwal PK et al. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005 Feb; 173(2):533-6.

80.Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007 Feb 1;109(3):536-41

81.Morgentaler A et al. Testosterone therapy in men with untreated prostate cancer. Journal of Urology 2011 Apr;185(4)9.

82.Abramow M., Corvilain J.: Metabolic effects of human growth hormone in adults and children. J Ann Endocrinol (Paris) March-April 1963, 145-56.

83.Hernberg-Stahl E, Luger A, Abs R, Bengtsson BA, Feldt-Rasmussen U, Wilton P, Westberg B, Monson JP; KIMS International Board., KIMS Study Group. Pharmacia International Metabolic Database, "Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency," J Clin Endocrinol Metab. 2001 Nov;86(11):5277-81.